At the IGTP TODAY
The conference has been a meeting point and an opportunity to share strategies, knowledge and innovative projects that contribute to improving the health and quality of life of people affected by cancer. Pere Torán and Federico Fondelli, researchers affiliated with IGTP, have been recognised in the 2025 Research Awards.
_1762445197.png)
The event gathered more than 200 researchers, reviewing the Institute's scientific trajectory and looking ahead to the future of research and innovation at the Can Ruti Campus.
Provides a new perspective: what matters is not only which previous diseases a person has, but also the order in which they appeared and how they interact. This approach makes it possible to identify risk profiles for long COVID that had not been detected until now. The research was conducted within the framework of the COVICAT study, coordinated in collaboration with ISGlobal.
A project led by the Germans Trias i Pujol University Hospital and Research Institute has developed an AI-based facial recognition system, AcroFace, capable of detecting early signs of acromegaly with 93% accuracy. The researchers are now conducting a larger pilot study with 4,000 images from the general population to confirm these promising results and improve early diagnosis of this rare disease.
_1746530699_1761816045.jpg)
The Institute has taken part in BIOSPAIN 2025, the leading biotechnology event in southern Europe, with the aim of strengthening its knowledge and technology transfer strategy, showcasing its innovation capabilities, and fostering new collaborations with companies, investors, and stakeholders across the biomedical ecosystem.
Researchers from the IGTP and HUGTiP have reviewed the current knowledge on the use of tear-derived extracellular vesicles as a source of biomarkers for both ocular and neurodegenerative diseases. They highlight the advantages of this approach compared with more invasive methods and discuss the remaining challenges for its clinical application.
The Fisabio Foundation, an organisation under the Department of Health, and IGTP have signed a framework agreement for scientific collaboration to jointly promote research in the field of AI and radiomics
The demonstration of the vaccine's efficacy in its preclinical phase was carried out at the Comparative Medicine and Bioimage Centre of Catalonia, a trategic project of IGTP.
IGTP strengthens its commitment to excellence in innovation management and consolidates its position as a leading research centre with the attainment of the international ISO 56001 certification. This milestone recognises the implementation of a consolidated innovation management system aligned with international standards.
A clinical trial involving 40 patients, led by IrsiCaixa and IGTP and conducted at HUGTiP, confirms that the RUTI® vaccine, owned by Archivel Farma, enhances the effectiveness of the current treatment for non-muscle-invasive bladder cancer.
